Document is current
Any future updates will be listed below
-
Authors
van Schaik, Mieke http://orcid.org/0000-0003-3823-4702
Arends, Eline J.
Soonawala, Darius
van Ommen, Ellen
de Leeuw, Karina
Limper, Maarten
van Paassen, Pieter
Huizinga, Tom W. J.
Toes, René E. M.
van Kooten, Cees
Rotmans, Joris I.
Rabelink, Ton J.
Teng, Y. K. Onno
-
Funding
Funding for this research was provided by:
GlaxoSmithKline (N/a)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (90713460)
Nierstichting (KJPB12.028, 17OKG04)
- License Information
-
More Information
Article History
Received: 21 April 2022
Accepted: 22 October 2022
First Online: 12 November 2022
Declarations
:
: The trial has been approved by the local medical ethics committee Leiden-The Hague-Delft (protocol identifier NL65720.058.18, reference number P18.087) and was registered in November 2018 at clinicaltrials.gov (NCT03747159). All participants provide written informed consent prior to participation. A model consent form may be available upon request. Substantial amendments will be proposed to the ethics committee and communicated with all relevant parties.
: Not applicable.
: YKOT has received research support and consulting fees from GlaxoSmithKline.
